<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21866">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02131012</url>
  </required_header>
  <id_info>
    <org_study_id>IND for Celecoxib</org_study_id>
    <nct_id>NCT02131012</nct_id>
  </id_info>
  <brief_title>Intraviteral Celecoxib for Chronic Uveitis</brief_title>
  <acronym>Celecoxib</acronym>
  <official_title>Intravitreal Celecoxib for Chronic Uveitis: A Phase I Investigational Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraocular delivery of celecoxib will be an effective means to treat inflammation and
      macular edema and prevent structural complications and vision loss in patients with chronic
      inflammation or macular edema who are unable to tolerate corticosteroids due to their side
      effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims I: Test the safety of intraocular injection of 1mg and 4mg celecoxib in
      patients who have chronic inflammation or macular edema who are unable to tolerate
      corticosteroids due to their side effects.

      II: Test the efficacy of intraocular 1mg and 4mg celecoxib in treating inflammation or
      structural complications of inflammation (macular edema) in patients who are unable to
      tolerate corticosteroids due to their side effects.

      After investigational new drug application and Vanderbilt IRB approval, celecoxib will be
      compounded by the Investigational Drug Service of the Vanderbilt Medical Center and packaged
      in individual sterile single use syringes for intraocular injection within 2 hours of
      preparation. Pharmaceutical grade celecoxib will be obtained from the drug manufacturer
      (Pfizer) with certificate analysis and compounded in sterile dimethyl sulfoxide following
      strict sterile technique.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participant will receive an intravitreal injection of the Celecoxib and be followed for any possible adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participant will receive the intravitreal injection of celecoxib day 1 and be followed for efficacy. The efficacy will be determined from the ophthalmic exams and aqueous samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-4 mg intravitreal injection ofCelecoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Celecoxib</intervention_name>
    <description>1-4 mg intravitreal celecoxib</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
    <other_name>NSAIDS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic inflammation and/or macular edema despite maximal medical treatment Unable to
             tolerate corticosteroids due to side effects Aphakic or Psuedophakic subjects

        Exclusion Criteria:

          -  15 years or younger Have active ocular infection Pregnancy Phakic subjects
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Stephen J. Kim, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Macular edema</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
